When should MTHFR genetic testing be ordered and what is the recommended treatment for a patient with a pathogenic MTHFR variant?

MTHFR Genetic Testing: Do Not Order Routinely

The American College of Medical Genetics and Genomics (ACMG) explicitly does not recommend routine MTHFR variant testing for thrombophilia, recurrent pregnancy loss, or other adverse perinatal events 1. This position is supported by ACOG and the British Committee for Standards in Haematology.

When MTHFR Testing Should NOT Be Ordered

• Not for routine thrombophilia evaluation - Recent meta-analyses show no significant association between common MTHFR variants (c.665C>T and c.1286A>C) and venous thromboembolism, coronary heart disease, or recurrent pregnancy loss 1, 2
• Not for reproductive carrier screening 1
• Not as part of general population screening
• Not for cardiovascular risk assessment - The MTHFR variant itself is not associated with arterial thrombosis in the absence of hyperhomocysteinemia 3

The common MTHFR polymorphisms (677C>T and 1298A>C) are found in 30-40% of the general population in heterozygous form and 10-15% in homozygous form 3. Their high prevalence and lack of proven clinical utility make routine testing inappropriate.

When MTHFR Testing IS Indicated

MTHFR genetic testing should be reserved for suspected severe MTHFR deficiency, which is a completely different clinical entity from common polymorphisms:

Clinical Presentations Warranting Testing:

• Neurological symptoms combined with biochemical findings of severe hyperhomocysteinemia and hypomethioninemia 4, 5
• Neonatal/early childhood onset of progressive neurological distress 6
• Unexplained severe hyperhomocysteinemia (>100 μmol/L) with neurological manifestations 7
• Atypical hemolytic uremic syndrome with metabolic abnormalities 4
• Subacute spinal cord degeneration of unclear etiology 4

Key Distinction:

Common MTHFR polymorphisms cause mild enzyme reduction, while severe MTHFR deficiency results in <10% enzyme activity with life-threatening consequences 6, 7.

Recommended Approach Instead of MTHFR Testing

For thrombophilia evaluation: Measure plasma total homocysteine directly rather than MTHFR genotype 3, 8. Homocysteine measurement is more informative because:

• Homozygosity for 677C>T accounts for only one-third of hyperhomocysteinemia cases 3
• Multiple factors beyond MTHFR affect homocysteine levels (B12, B6, folate status, renal function)
• Treatment decisions are based on homocysteine levels, not genotype

Use 15 μmol/L as the threshold for hyperhomocysteinemia 8, though values of 10-15 μmol/L may confer graded risk.

Treatment for Pathogenic MTHFR Variants

For Severe MTHFR Deficiency (True Disease):

Immediate treatment is life-saving and should not be delayed 4:

1. Hydroxocobalamin (parenteral) - Start immediately when severe MTHFR deficiency is suspected; significantly improves survival 4

2. Betaine - Strongly recommended; improves outcome and prevents disease progression when given early 4, 6, 7

3. Multivitamin supplementation including:

   • Folate (or preferably 5-methyltetrahydrofolate, which bypasses MTHFR) 9
   • Vitamin B12
   • Vitamin B6

4. Monitor treatment efficacy by measuring total homocysteine levels 8

For Common MTHFR Polymorphisms:

No specific treatment is indicated based on genotype alone 1, 2. If elevated homocysteine is present:

• For moderate hyperhomocysteinemia (15-30 μmol/L) with MTHFR 677TT genotype: Consider oral 5-methyltetrahydrofolate (5-MTHF) since this bypasses the MTHFR enzyme 9
• Standard folic acid supplementation (400 μg/day RDA) reduces homocysteine by 25-30% 9
• Address underlying causes: folate deficiency, B12 deficiency, renal dysfunction, hypothyroidism

Critical Pitfalls to Avoid

1. Do not confuse common polymorphisms with severe deficiency - They are entirely different conditions with different implications
2. Do not order MTHFR testing reflexively for recurrent pregnancy loss or thrombosis workup
3. Do not use high-dose folic acid in populations already receiving folate fortification (North America) - it provides no additional vascular benefit 9
4. Do not supplement with folate alone without checking B12 status - this can mask B12 deficiency while allowing neurological damage to progress 8
5. Do not make clinical decisions based on MTHFR polymorphism status for VTE risk stratification 1

The evidence is clear and consistent across multiple professional societies: routine MTHFR polymorphism testing lacks clinical utility and should be discontinued in standard practice.